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Abstract: 188Re Zoledronic acid (188Re-ZA) is new radiopharmaceutical which may have advantages over other bone 
seeking β-emitters due to high radiation energy of 188Re, and metabolic effect of zoledronic acid. 
In the phase I-II of the study therapeutic dosage of 188Re-ZA was estimated. Pharmacokinetics, dosimetry and safety 
were assessed in the dose escalation study. Twenty-one (3, 3 and 15) breast and prostate cancer patients with multiple 
painful bone metastases received 35, 45 and 55 MBq of 188Re-ZA respectively. In the next step 42 new patients were 
randomized in 2 groups (188Re-ZA in dosage of 45 MBq/kg and 89SrCl2 in dosage of 150 MBq) to assess safety and 
efficacy of the radiopharmaceuticals, the follow up lasted for 9 weeks.  
Absorbed dose to the bone marrow is respectively low 0.26±0.06 Gy. The dose escalation study shows that 188Re-ZA the 
dosage of 55 MBq/kg is safe, no significant hematologic or any other toxicity is observed. 89SrCl2 in a dosage of 150 
MBq, as compared to 188Re-ZA in a dosage of 45 MBq/kg demonstrates similar efficacy, but the effect starts faster in 
188Re-ZA group. By the end of the follow up some patients demonstrated pain recurrence, this may indicate the need for 
repeated courses of treatment. Though many patients with widespread bone metastases and the higher base level of 
alkaline phosphatase were in the 188Re-ZA group, in the majority of cases of both groups stabilization of the disease was 
achieved and continued for at least two months. Both radiopharmaceuticals demonstrated acceptable safety profile. 
Although trend in reduction of hemoglobin level was observed, especially in the group of patients with baseline anemia, 
both radiopharmaceuticals significantly impact on the platelet counts (PLT) only. As it was predicted by dosimetry data, 
188Re-ZA in a dose of 45 MBq/kg is safer, by the week 6 the PLT counts in the 188Re-ZA group became almost the same 
as baseline and even higher in the week 9, while in the 89SrCl2 group in the week 9 PLT counts remained below the 
baseline; the difference was statistically proven. It seems that patients with breast cancer, in contrast to those with 
prostate cancer, have benefit (not statistically significant) in overall survival: 20.7 vs 15.6 months regardless dosage or 
type of radiopharmaceutical. 
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INTRODUCTION 
For long time bone seeking radiopharmaceuticals 
are used to palliate painful bone metastases. Great 
part of scientific work in this area is focused on prostate 
and breast cancers. These types of cancers are 
characterized by frequent multiple bone metastases 
with no visceral lesions. [1]. Life expectancy of this kind 
of patients may be relatively long [1], so it is important 
to preserve their quality of life. Only three bone seeking 
radiopharmaceuticals are registered in Russia. 89SrCl2 
and 153Sm-EDTMP are the most commonly used to  
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decline pain syndrome and reduce analgesic intake. 
The newest bone seeking agent 223Ra dichloride also 
has benefit in overall survival of patients with castration 
resistant prostate cancer and predominantly skeleton 
involvement [2]. As for 89SrCl2 it is very simple to 
handle and administer, but it is recommended for use 
in cases of light to moderate pain syndromes and not 
widespread (less than 10 metastases) disease [3]. 
Unfortunately, these types of clinical situation are 
relatively rare. Due to its physical characteristics 153Sm-
EDTMP can be safely used for larger bone 
involvements, and its effect is faster, so it can help to 
manage severe pain [3]. As for 223Ra dichloride it is 
registered only for castration resistant prostate cancer 
patients and it is the most expensive one [4]. Despite 
the fact, that 223RaCl2 is the gold standard of care of 
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patients with multiple bone metastases, due to its high 
cost it is hardly available for majority of the prostate 
cancer patients in Russia and around the world. In 
addition, we still have no recommendations on the use 
of 223RaCl2 in cases of other malignancies (not CRPC) 
with multiple painful bone metastases. Thus, the 
search for new radiopharmaceuticals is an important 
challenge. The new radiopharmaceutical based on 
188Re and Zoledronic acid may become an alternative 
to traditionally used bone seeking agents.  
MATERIALS AND METHODS 
Preparation of 188Re Zoledronic Acid (188Re-ZA) 
188Re perrhenate (radiochemical purity 99.7%,  
PH 4.1) was obtained from in-house 25 GBq 188W/188Re 
generator (Institute of Physics and Power Engineering, 
Obninsk). The generator was eluted with 5-9 ml of 
0.9% saline. 1-2 ml of eluate was mixed with the 
preparation kit of 4 mg zoledronic acid lyophilizate 
(Pharm-Sintez, Moscow). The solution was heated at 
95° C for 30 min, after cooling to room temperature the 
solution was passed through the sterilizing filter 
“Millipore” with the diameter of the pores 0,22 
micrometers. Then it is added to 15 milliliters of saline 
solution and applied to patient by syringe pump for 15 
minutes. 
Quality control of 188Re-ZA was performed using 
thin-layer chromatography developed with acetone or 
physiological saline. The levels of impurities detected in 
patient samples were always less than 5%.  
Study Design 
This study consisted of two parts. The aim of the 
first part was to assess the maximum tolerated dose of 
the radiopharmaceutical and estimate therapeutic 
dose. The first three patients had to receive the drug at 
a rate of 35 MBq/kg, after 8 weeks of safety 
assessment in the event of any dose-limiting toxicity 
(DLT) the group had to be expanded to 6 patients. In 
case of DLT in 2 subjects, the study had to be 
completed; otherwise it was necessary to recruit the 
next group of three with administration activity of 45 
MBq/kg. Like in previous situation, in case of DLT the 
second group also had to be enlarged to 6 patients. If 
revealed 2 cases of DLT, the therapeutic dosage would 
be estimated as 35MBq/kg. In another case, it was 
necessary to recruit the third group of patients (55 
MBq/kg), in case of DLT revealed during follow up 
period, the third group also had to be expanded to 6, if 
revealed 2 cases of DLT the therapeutic dosage would 
be estimated as 45 MBq/kg. In case of only one or no 
DLT revealed the therapeutic dosage would be 
estimated as 55 MBq/kg. In any case the group of 
therapeutic activity had to be enlarged up to 15 patients 
in order to have more statistically significant data. The 
DLT was equal for the following events: neutropenia of 
grade IV or fever caused by neutropenia, grade IV 
platelet counts decrease or grade III thrombocytopenia 
lasted more then 7 days, any other grade III-V adverse 
event associated with the use of an investigational 
drug.  
In the second part of the study safety and efficacy of 
188Re-ZA had to be assessed in comparison to 89SrCl2 
on a randomized multicenter basis. The history of use 
of 188Re-HEDP in Russia is limited only to clinical trials, 
and 186Re-HEDP has never been used. 89SrCl2 is used 
in the majority of the nuclear therapy centers in Russia, 
but only two centers have experience in 153Sm-EDTMP 
application. Therefore, 89SrCl2 was chosen as a compa- 
rative drug. Changes in quality of life, intensiveness of 
pain syndrome and metabolic response (according to a 
bone scan) were selected as effectiveness criteria. 
After active part of the investigation all patients entered 
into long term follow up period with assessment of 
overall survival. 
Inclusion Criteria 
Patients with histologically proven prostate or breast 
cancer and CT proven multiple (3 or more) painful 
(required analgesic intake) bone metastases with 
positive 99mTc Zoledronic acid uptake, with no history of 
visceral metastases and no additional malignances 
were included in the study. Subjects with changes in 
hormone therapy, received external beam therapy or 
chemotherapy 1 month prior to screening were not 
included. Sufficient bone marrow function was required: 
platelet count not less than 100 thousand/ml, leukocyte 
count not less than 3.0 thousand/ml and hemoglobin 
level not less than 80 g/l. 
Patients 
The study was approved by the local ethics 
committee. All patients included in the study were 
informed about the study, possible risks of participation 
and signed the informed consent form. 
According to the study design the first 3 patients 
with multiple painful bone metastases of prostate or 
breast cancer received 188Re-ZA in dosage of 35 
MBq/kg, as no cases of DLT appeared in follow up 
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period, the next 3 received 45 MBq/kg, and the third  
3 – 55 MBq/kg, after 9 weeks of follow up the third 
group was enlarged up to 15 patients. All patients had 
previously done bone scan with 99mTc Zoledronic acid, 
theranostic pare to 188Re-ZA, 3 or more bone lesions 
were confirmed in each case. In the first day after 
administration dosimetry data were collected: 1, 4, 20, 
26-28 hours after administration there was anterior and 
posterior whole body scanning performed (gamma-
camera Mediso with high-energy collimator). Regions 
of interests were processed anterior and posterior: 
metastatic lesions, significant organs and tissues. Half-
life time (Teff), fractions of organs and absorbed doses 
were calculated using MCNP 4 code and program 
OLINDA/EXM 1.0. Safety assessment performed 
during the first 3 days after administration and then 
weekly up to week 9. For this issue, blood counts, liver 
and kidney function biomarkers (ALT, AST, creatinine, 
urea, etc) were obtained. Physical examination, 
electrocardiogram and urine tests were performed on a 
regular basis. 
For the efficacy assessment 42 patients were 
included in the study, after screening they were 
randomized into 188Re-ZA group and 89SrCl2 group, 21 
subjects for each group. Basic demographic data and 
screening characteristics of subjects are on the  
Figure 1. All patients kept a diary of pain and 
consumption of analgesics a week prior and during 
follow up period after administration of 45/kg MBq 
188Re-ZA or 150 MBq 89SrCl2. In the diary, they daily 
described their pain in various parts of the body for a 
10-point visual analog scale. Quality of life was 
evaluated using the SF-36 questioner, which was filled 
prior therapy and on the 28th and 56th day after. Safety 
control was performed by the method similar to that 
used in the first part of the investigation. All patients 
underwent bone scan with 99mTc Zoledronic acid in 
order to assess metabolic response.  
RESULTS 
Therapeutic Dosage of 188Re-ZA 
In this study 188Re-ZA did not demonstrate 
significant toxicity in any subgroup. In the group 
received 55MBq/kg of the radiopharmaceutical 
reversible short term neutropenia grade III was 
observed only once in breast cancer patient, who 
previously received multiple cycles of chemotherapy. 
The studied group  
Subjects characteristics 
(screening)  188Re-ZA 35 
MBq/kg 
188Re-ZA 45 
MBq/kg (part 1) 
188Re-ZA 55 
MBq/kg 
188Re-ZA 45 
MBq/kg (part 2) 
150 MBq 89Sr 
chloride 
Number of subjects 
(prostate and breast 
cancer) 
3 
2 and 1 
3 
1 and 2 
15 
4 and 11 
21 
10 and 11 
21 
11 and 10 
Age (years) of prostate 
cancer ones 81 and 64 77 52, 55, 59 and 68 
From 53 to 80, 
median 67 
From 59 to 74, 
median 65 
Age (years) of breast 
cancer ones 57 66 and 67 
From 30 to 67, 
median 51 
From 35 to 69 
median 59 
From 45 to 77 
median 55 
Number of patients divided in 4 groups depending on number of lesions found on bone scan: 
From 3 to 6 1 (33%) 0 1 (7%) 2 (10%) 4 (19%) 
From 6 to 20 0 0 5 (33%) 5 (24%) 5 (24%) 
More then 20, but not total  2 (67%) 2 (67%) 1 (7%) 5 (24%) 5 (24%) 
Multiple lesions from scull 
to long bones  0  1 (33%) 8 (53%) 9 (43%) 7 (33%) 
ALP level U/L (range and 
mean +/- SE) 48, 71 and 190 171, 234 and 905 
43 to 961, mean 
238 +/-62 
57 to 1880, mean 
345 +/- 98 
61 to 508, mean 155 
+/-27 
HGB level g/l (range and 
mean +/- SE) 
116, 120 and 
139 113, 125 and 136 
91 to 144, mean 
126 +/-4 
85 to 148, mean 
124 +/-4 
102 to 156, mean 
132 +/-4 
PLT 109/L (range and mean 
+/- SE) 
171, 197 and 
240 250, 283 and 435 
137 to 363, mean 
241 +/-15 
143 to 347, mean 
218 +/-14 
129 to 564, mean 
245 +/-20 
WBC 109/L (range and 
mean +/- SE) 3.8, 6.7 and 6.9 6.2, 7.5 and 9.1 
3.3 to 9.5, mean 
6.5 +/- 0.5 
3.9 to 13.6, mean 
6.9 +/-0.5 
4.2 to 13.4, mean 
7.4 +/-0.6  
Figure 1: Basic demographic data and screening characteristics of subjects included into the study. 
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Thus, DLT was not observed and 188Re-ZA can be 
safely administered in dosage of 55 MBq/kg. However, 
according to the experts’ opinion, estimated therapeutic 
dosage was 45 MBq/kg. This opinion was based on the 
idea that this kind of treatment might be more effective 
if it is repeated several times with relatively short 
intervals. The dosage was reduced to avoid any kind of 
cumulative toxicity in case of multiple cycles.  
Dosimetry 
During the first part of the study dosimetry 
measurements were carried out. Urine samples 
demonstrated rapid excretion of the drug, more than 
90% excretion accounted for the first 4 hours after 
administration. Half-life (Teff) in bone metastasis 
(10.7±3.7 h) depended on their size and uptake of the 
radiopharmaceutical; it was significantly higher than in 
a whole body (6.3±0.7 h), normal organs and bones. 
Variation of Teff determines variability of specific 
absorbed dose, which was adjusted to therapeutic 
activity of 45 MBq/kg. Absorbed dose in metastases 
varied from 4.68 to 43.89 Gy (tumor volume ranges 
from 14 to 70 cm3), which is sufficient to achieve 
therapeutic effect. Absorbed dose in kidneys 
(2.73±0.67 Gy) and urinary bladder (4.24±1.52 Gy) 
were less than maximally acceptable of 10 Gy. In this 
study, it was found that absorbed dose to the bone 
marrow was 0.26±0.06 Gy, it is significantly lower than 
those for other commercially available bone seeking 
 35 MBq/kg 45 MBq/rg 55 MBq/kg all 
PLT decrease 2 (67%)   9 (60%) 11 (52%) 
Anemia   2 (67%) 5 (33%) 7 (33%) 
Anemia grade II     2 (13%) 2 (10%) 
WBC decrease 3 (33%) 1 (33%) 5 (33%) 7 (33%) 
WBC decrease grade II     2 (13%) 2 (10%) 
Neutropenia     4 (27%) 4 (19%) 
neutropenia grade II     1 (7%) 1 (5%) 
neutropenia grade III     1 (7%) 1 (5%) 
PLT increase     4 (28%) 4 (19%) 
WBC increase     3 (20%) 3 (14%) 
HGB increase     1 (7%) 1 (5%) 
hypercalcemia     3 (20%) 3 (14%) 
hypocalcemia   1 (33%) 1 (7%) 2 (10%) 
uremia     1 (7%) 1 (5%) 
flare effect 3 (100%) 2 (67%) 7 (47%) 12 (57%) 
flu like syndrome     3 (20%) 3 (14%) 
flu like syndrome grade II     1 (7%) 1 (5%) 
bone pain reccurence 3 (100%)   3 (20%) 6 (29%) 
Urethritis 1 (33%)   6 (49%) 7 (33%) 
nausea   1 (33%) 1 (7%) 2 (10%) 
vomiting     1 (7%) 1 (5%) 
anxiety     2 (13%) 2 (10%) 
disorientation 1 (33%)     1 (5%) 
local reaction     2 (13%) 2 (10%) 
headache      1 (7%) 1 (5%) 
arthrosis     1 (7%) 1 (5%) 
Figure 2: List of adverse events possible related to study medication. The data collected during the first part of the study 
(therapeutic dose determination and safety assessment). 
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radiopharmaceuticals like 153Sm-EDTMP (1.1 Gy) or 
even 188Re-HEDP (2.0±0.6) [5].  
Safety 
According to the study design administered activity 
of 188Re-ZA was ranged from 2.7 to 5.8 GBq. In this 
study, adverse events were classified according to the 
NCI CTC AE v 4.0. In generally the therapy was well 
tolerated (Figure 2), only one serious adverse event 
(SAE) was reported in the group of 55 MBq/kg. 
Hormone refractory prostate cancer patient with rapid 
disease progression and severe pain syndrome (opioid 
use required) needed to prolong his stay at hospital 
due to the grade II flu-like syndrome (3 days of fever) 
and flare phenomenon which decreased his 
Karnofsky's scale from 60% to 40%. Two weeks later 
this patient was pain free with no more opioid intake 
and 70% Karnofsky's scale, there were not additional 
treatments of any kind and unfortunately 3.6 months 
later he died due to disease progression. Almost half of 
the patients noted the flare effect, which was 
manifested by a slight increase in pain or an increase 
in analgesics consumption. Flu like syndrome was 
documented in 14% of cases. By the end of the follow 
up period some patients (predominantly with prostate 
cancer) demonstrated bone pain recurrence that might 
be an indication for additional treatment cycle. Most 
common adverse effects which may have any 
connection to the study drug are listed on the Figure 2. 
The most important adverse event of bone seeking 
radiopharmaceuticals is hematological toxicity. Platelet 
counts (PLT) is the unique setting which was found to 
be statistically significantly assosiated with the therapy. 
We have also identified significant differences between 
the two study drugs. Nevertheless, 188Re-ZA was well 
tolerated in all subgroups of activity: 9 (60%) and 12 
(63%) cases of grade I PLT decrease were found in 55 
MBq/kg and 45 MBq/kg subgroups respectively, nadir 
was registered at the week 4 after the treatment date 
and the average PLT reduction was 12% (55 MBq/kg) 
and 17% (45 MBq/kg) respectively; and one case of 
reversible PLT counts grade II decrease was registered 
in one prostate cancer patient from the 45 MBq/kg 
group, his base PLT count was - 103x109/l, by the 
week 9 it rose up to 125 x109/l. No difference between 
the dosages of 45 MBq/kg and 55 MBq/kg (see Figure 
3) was found. As for 89SrCl2, in generally it was also 
well tolerated. No flu like syndrome was revealed, flare 
phenomenon also was not documented, but in one 
case (castration resistant prostate cancer) 
unexpectedly pancytopenia was developed, which 
finely led to death. Except this one extraordinary case 
there was only grade I toxicity in 9 cases (45%). The 
differences between 188Re-ZA and 89SrCl2 are shown 
on the Figure 4. We presented data on those patients, 
who successfully completed the study without any 
protocol deviations, we excluded 2 women with disease 
progression (found brain metastases and pleura 
canceramatosis) from 188Re-ZA drug arm, as for 89SrCl2 
arm, 2 men with progression of the disease, they could 
not follow the schedule of visits due to worsening of 
their general condition, 4 other patients missed at least 
one visit for different reasons and didn’t take part in the 
evaluations. Remarkable, in the patient with severe 
PLT counts decrease necessary platelet transfusion at 
the week 8 of follow up, however this extraordinary 
case had not any influence on the final analysis. As it 
shown on the Figure 4, PLT counts are better in the 
89SrCl2 group (but not statistically significantly). At the 
week 1 unexpected increase in PLT counts in the 
188Re-ZA group was found. 188Re-ZA acid PLT 
dynamics curve has a nadir at the week 4, then it goes 
up, is close to the screening value at the week 6, at the 
week 9 it is even better than before the treatment. 
89SrCl2 curve also seems to have a slight increase at 
the week 1, but its nadir is registered at the 5th week, 
after that the curve goes up slowly and doesn’t reach 
initial values by the end of the follow up. Multivariate 
analysis of variance for repeated measures was used 
to found statistical differences between the two groups, 
and it was found with p value about 0.024. This 
distinction is very important for patients, who may need 
frequent retreatments to manage multiple painful bone 
metastases or some kind of chemotherapy in case of 
any needs. 
 
Figure 3: Platelet count (PLT) dynamics after administration 
of 55 MBq/kg or 45 MBq/kg of 188Re-ZA. The number of 
valid (without missing points) cases were 12 and 19 
respectively. 
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Figure 4: Platelet count (PLT) dynamics after administration 
of 45 MBq/kg of 188Re-ZA or 150 MBq of 89SrCl2. The number 
of valid (without missing points) cases were 18 and 15 
respectively. 
As for other blood parameters, we noticed slight, not 
statistically significant, decrease of hemoglobin (HGB) 
level and white blood cell counts (WBC) after 
administration of 188Re-ZA or 89SrCl2 with no difference 
depended on the drug or its dosage. There were two 
cases of anemia grade II. The first occurred in the 
previously described patient from the 188Re-ZA 55 
MBq/kg group, the HGB level declined from 91 to 81 g/l 
with subsequent full recovery. The other case also 
appeared in hormone refractory prostate cancer 
patient: HGB level dropped down from 107 g/l to 97 g/l 
by the end of the follow up period. We did not found 
any statistically significant changes in influence on 
HGB level between 188Re-ZA and 89SrCl2. There were 3 
cases (16%) of anemia grade III in 188Re-ZA group. All 
subjects were previously anemic with HGB level 
dropped from 91, 86, and 85 g/l to 79, 70 and 74 g/l 
respectively. Remarkably, two anemic patients had 
progressive hormone refractory prostate cancer after 
multiple cycles of chemotherapy and one breast cancer 
patient demonstrated specific hemorrhagic pleural 
effusion 5 weeks after administration. In addition, there 
was 1 case (5%) of anemia grade II in hormone 
refractory prostate cancer patient which had anemia 
grade I at the screening time. In the 89SrCl2 group no 
patients with HGB level below the rate 100 g/l at the 
screening time were included, but 1 case (5%) of grade 
III anemia also was reported in man with previous 
grade I anemia, and 4 cases (20%) of grade II anemia 
were found, only one of them had normal HGB level at 
the time of administration. In both groups, there were 
patients with normal HGB level at the time of 
administration who did not demonstrate any decline of 
the HGB level at all. The data shows that some 
circumstances, like disease progression, bone marrow 
involvement and others, in addition to medications can 
affect the severity of anemia. In all groups of subjects 
WBC counts fluctuated in normal range, those patients 
who initially had WBC count higher than normal level 
tended to have a decline after treatment. In patients, 
who were heavily pretreated with chemotherapies, 
some cases of hematological toxicity were 
documented. In 188Re-ZA (55 MBq/kg) group 4 cases 
(27%) of grade I and 2 cases (13%) of grade II 
reversible WBC decrease was found, in 188Re-ZA (45 
MBq/kg) 5 cases (26%) of grade I WBC decrease were 
documented, in the 89SrCl2 group 6 cases (30%) of 
grade I and 1 case (5%) of grade II WBC decrease 
were found. 
Efficacy 
The main idea of the efficacy analysis was to 
evaluate the influence of administration of 188Re-ZA or 
89SrCl2 on the average severity of pain. For this issue 
the area under the pain-time curve (AUC) was 
calculated for the 7 days of screening period and 
weekly after the treatment. For comparative analysis, 
the generalized linear model was used. In our small 
study (19 and 18 valid subjects who completed all 
diaries in 188Re-ZA and 89SrCl2 group respectively) 
there was not found any statistically significant 
deference. In both groups, there were some cases with 
severe pain syndrome which was refractory to 
treatment demonstrated only aggravation during the 
follow up period. These few cases have a great impact 
on the means, thus the medians reflect the real 
dynamic much more accurately. As one can see on the 
Figure 5, patients treated with 89SrCl2 had better initial 
conditions, in the 1st 3 weeks we can not see any 
positive changes, this data is well correlated with 
already known property of 89SrCl2. From the week 3 the 
AUC pain-time curve goes down but unfortunately does 
not reach its nadir. So, we can’t make any conclusions 
neither about decline degree nor about duration of 
effect. Contrary, 188Re-ZA demonstrated fast analgesic 
effect. Feeling better many patients tried to reduce their 
daily analgesic intake, what was the reason of pain 
recurrence at the week 2. After this peak the curve 
continues to decrease till its nadir at the week 5, 
average of decrease at this point compared to the 
screening time is 25.47% for the medians and 10.47% 
for the means. At the end of the follow up period there 
was a tendency to evidence of pain recurrence 
followed with a return to analgesics use. At the week 9 
only 4 (21%) patients still demonstrated 50% reduce in 
the index of analgesic intake, while in 89SrCl2 group at 
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its best time of action 6 (33%) subjects had 50% or 
more reduction of this index. To conclude, these even 
not statistically significant tendencies may indicate a 
need for different therapeutic approaches in use the 
investigational drugs.  
 
Figure 5: Area under the curve “Pain-Time” (AUC) at the 
screening week and after administration of investigational or 
control radiopharmaceutical. 
As for quality of life at the week 4 the dynamics of 
the integral index of quality of life (IQL) was better in 
188Re-ZA group than in 89SrCl2 one (+10% and +3% 
respectively). Like in previous analysis results for 
89SrCl2 group were better at the week 9, IQL reached 
+7%, while in 188Re-ZA it was measured +6% 
compared to the screening condition. These 
differences however did not reach statistical 
significance. In subgroup analysis, we found that in the 
breast cancer group 188Re-ZA was managed to 
improve physical component of quality of life (-2% at 
the week 4 and +21% at the week 9), while 89SrCl2 
failed to improve it (-3% at the week 4 and -1% at the 
week 9). The differences between 188Re-ZA and 89SrCl2 
arms were statistically significant according to the 
Wilcoxon test (p <0.05). In male patient group any 
statistically significant differences were not found.  
Metabolic Response 
All patients had bone scan with 99mTc-ZA prior to 
administration of 188Re-ZA or 89SrCl2, those who 
successfully completed the study had control bone 
scan on the last visit, at the week 9. Alkaline 
Phosphatase (ALP) was measured weekly before and 
after the administration. In both groups, more than half 
patients had wide spread bone metastases (more than 
20 lesions), see Figure 1. Unfortunately, we found 
statistically significant difference between the main and 
control group in the baseline ALP level, which, as 
known, correlates with prognosis. In the 188Re-ZA 
group it was significantly higher. Generalized linear 
model was used to assess influence of the therapy on 
the ALP level, which can reflect metabolic response, 
see Figure 6. In this study, there was not any 
differences between initial and follow up ALP level; it 
was stable in both groups. In individual analysis, by the 
end of the follow up period we found 2 cases (12%) of 
ALP progression (more than 30% ALP level increase) 
and 3 cases (18%) of response (more than 30% ALP 
level decrease) in the 188Re-ZA group. In 89SrCl2 group 
there were 2 cases of progression (11%) and only 1 
responder (5%). As for imaging, we saw generally 
stable disease or mix response, there were 4 cases 
(20%) of 2 or more new active bone lesions on bone 
scan in the 188Re-ZA group and 5 (25%) in the 89SrCl2 
group. We also found one case (5%) of clear metabolic 
response (two lesions disappeared) in the control 
group.  
 
Figure 6: ALP dynamics after administration of 188Re-ZA (45 
MBq/kg) or 89SrCl2 (150 MBq). 
Survival 
All patients included in the study and received 
treatment entered into survival analysis. Some of them 
unfortunately were lost for long term follow up, but the 
data is still collected, so this time we can present only 
preliminary results. We assessed overall survival (OS) 
in 3 groups of patients: 188Re-ZA 55 MBq/kg, 188Re-ZA 
45 MBq/kg and 89SrCl2 150 MBq. The results are 
presented on the Figure 7, The curves are very close to 
each other, median OS was 17,9 months for 188Re-ZA 
55 MBq/kg (15 subjects), 15,8 months for 188Re-ZA 
group 45 MBq (24 subjects) and for 89SrCl2 150 MBq 
(21 subjects) the OS still not estimated. No statistically 
significant difference between the groups was found, 
so we tried to compare OS in men (28 subjects) and 
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women (35 subjects), see Figure 8. It seems that life 
expectancy in breast cancer patients (median OS – 
20,7 months) is better than in prostate cancer males 
(median OS – 15,6 months), but the difference is not 
statistically significant.  
 
Figure 7: Overall survival by groups: 188Re-ZA 55 MBq/kg, 
188Re-ZA 45 MBq/kg and 89SrCl2 150 MBq. 
 
Figure 8: Overall survival in breast and prostate cancer 
patients after one cycle of bone seeking radiopharmaceutical. 
DISCUSSION AND CONCLUSION 
188Re-ZA is promising radiopharmaceutical for 
treatment painful bone metastases. Firstly, we noticed 
a great difference in pharmacokinetic compared to 
other bone seeking radiopharmaceuticals and even 
188Re-HEDP [5], Zoledronic acid has the highest affinity 
to bone lesions (compared to other phosphonates) with 
minimal accumulation in healthy bones [6]. As result, 
therapeutic absorbed doses in bone lesions can be 
achieved with relatively low bone marrow irradiation. 
Features of the distribution allow using 188Re-ZA in 
higher dosages than 188Re-HEDP: 55 MBq/kg (up to 
5.8 GBq) of 188Re-ZA is safe and acceptable while for 
188Re-HEDP therapeutic activity was estimated as 3.3 
GBq [7]. Bone seeking radiopharmaceuticals are well 
tolerated; well known dose limiting toxicity is a delayed 
decrease in the number of blood counts, mainly PLT. 
The decrease in the PLT counts by the week 4 after the 
administration, apparently, is a common feature of 
bone seeking radiopharmaceuticals, a similar trend 
recorded for 153Sm-EDTMP [8]. In this study, we didn’t 
found any significant impact on WBC or HGB level of 
the both drugs, but there was a tendency to HGB level 
decline, especially in anemic subjects. In this cases 
anemia may be the consequence of bone marrow 
involvement and disease progression, previous 
cytotoxic regimens or malabsorption and malnutrition. 
The influence of therapy on the severity of anemia 
remains not clear. But in fact, inclusion criteria were 
very wide allowing anemic patients with HGB level 
below 100 g/l to be involved in this study. There were 2 
anemic patients with HGB level 86 g/l and 1 patient – 
91 g/l. They all demonstrated worsening the anemia 
down to grade III which reversed by the end of the 
follow up period only in one case. In contrast, no 
decline in HGB level in non-anemic persons was found.  
According to the study the therapy had clear 
influence on PLT counts. In previous investigations no 
difference between various bone seeking 
radiopharmaceuticals (153Sm-EDTMP, 188Re-HEDP and 
89SrCl2) was found [9]. 188Re-ZA is the first one that 
demonstrated preferable safety profile compared to 
89SrCl2. That is very important for planning 
retreatments or combinations with other cytotoxic 
regimens. The case of unexpected pancytopenia in 
previously clinically stable prostate cancer patient also 
noteworthy. There is not any clear data about 
limitations in 89SrCl2 usage, IAEA recommends not to 
use it in cases with more than 10 bone lesions 
(according to bone scan) [3], however, no national or 
other recommendations related to this subject; in the 
study 57% patients from the control group, who 
received 89SrCl2, had more than 20 bone lesions. Thus, 
that is a question for further investigations. Despite the 
fact that patients treated with 188Re-ZA had worse base 
condition (higher ALP level), than patients of the control 
group, both radiopharmaceutical demonstrated similar 
efficacy. But 188Re-ZA acts faster and there is a 
tendency to pain recurrence in some cases at the week 
9, while analgesic effect of 89SrCl2 starts two weeks 
later and by the week 9 it appears to be maximum. 
Thus 188Re-ZA is more suitable for those who suffer 
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from severe uncontrolled or progressive pain 
syndrome. Breast cancer patients from the 188Re-ZA 
group had statistically significant benefit in physical 
component of IQL. Both radiopharmaceuticals were 
able to achieve stabilization in ALP level. 
The study is too small to draw any evidence-based 
conclusions about survival, however, it should be noted 
that we have not found any significant difference 
between patients received a single cycle of 89SrCl2 or 
188Re-ZA in different dosages. It seems that breast 
cancer patients have better prognosis than prostate 
cancer ones, in order to prove this, we need more data. 
In any case, our survival rates look good compared 
with findings from other studies [10], including large 
randomized trials like ALSIMPCA trial [11]. That is 
encouraging and inspires further research in the field of 
application of bone seeking β-emitters.  
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